Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dose Finding Phase (MTD) Clear all
Completed Phase 1 Interventional

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

NCT01839097
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Belinostat, CHOP
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
New Haven, Connecticut • Athens, Georgia • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional

Anti-SARS Cov-2 T Cell Infusions for COVID 19

NCT04401410
View directory record Official record
Conditions
SARS-CoV 2, Viral Infection, COVID 19
Interventions
Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs)
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

NCT00958022
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LBH589 and carboplatin with etoposide
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

NCT01201694
View directory record Official record
Conditions
Advanced Cancers
Interventions
Surface-Controlled Water Soluble Curcumin, Surface-Controlled Water Soluble Curcumin MTD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 5, 2026, 4:04 AM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

NCT07374029
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions
DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
Biological · Drug
Lead sponsor
David Avigan
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

NCT00005967
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

NCT00426582
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Norwalk, Connecticut • Rockville, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 5, 2026, 4:04 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

NCT06922539
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 5, 2026, 4:04 AM EDT
Withdrawn Phase 1 Interventional

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

NCT00682279
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
oral topotecan (SK&F-104864); lapatinib (GW572016)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

NCT02632721
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Decitabine, BI 836858
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Chicago, Illinois • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

NCT00195260
View directory record Official record
Conditions
Neoplasms
Interventions
bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Birmington, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Calcitriol in Lung Cancer

NCT00794547
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Calcitriol
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 5, 2026, 4:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

NCT05845671
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Duarte, California • Aurora, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

NCT01468688
View directory record Official record
Conditions
3rd Line GIST
Interventions
STI571, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 5, 2026, 4:04 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT04739813
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Interventions
obinutuzumab, prednisone, Revlimid, Polatuzumab, ibrutinib, venetoclax
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

NCT04951778
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
CC-91633
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 5, 2026, 4:04 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT05560399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

NCT01735968
View directory record Official record
Conditions
3rd Line GIST
Interventions
ST571 + BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

NCT02525029
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pregnyl®
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 76 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional Results available

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

NCT02511184
View directory record Official record
Conditions
ALK-positive Advanced NSCLC
Interventions
Crizotinib, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

NCT05085977
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Results available

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

NCT01587703
View directory record Official record
Conditions
Carcinoma, Midline
Interventions
GSK525762
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

NCT02365766
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Consolidative Surgery
Drug · Procedure
Lead sponsor
Jason R. Brown
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

NCT01421524
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 5, 2026, 4:04 AM EDT